IN THE HIGH COURT OF AUSTRALIA
Office of the Registry
Sydney No S300 of 2013
B e t w e e n -
ALPHAPHARM PTY LTD ACN 002 359 739
Applicant
and
H LUNDBECK A/S
First Respondent
COMMISSIONER OF PATENTS
Second Respondent
ASPEN PHARMA PTY LTD ACN 075 449 594
Third Respondent
SANDOZ PTY LTD ACN 075 449 553
Fourth Respondent
APOTEX PTY LTD ACN 096 916 148
Fifth Respondent
Application for special leave to appeal
KIEFEL J
KEANE J
TRANSCRIPT OF PROCEEDINGS
AT SYDNEY ON FRIDAY, 11 APRIL 2014, AT 11.06 AM
Copyright in the High Court of Australia
____________________
MR D.K. CATTERNS, QC: May it please the Court, I appear with my learned friends, MR C. DIMITRIADIS and MR J.S. ZMOOD, for the applicant and the fourth respondent. (instructed by King & Wood Mallesons).
MS K.J. HOWARD, SC: If the Court pleases, I appear with MR R.M. NIALL, SC, for the first respondent. (instructed by Corrs Chambers Westgarth Lawyers)
KIEFEL J: Yes, Mr Catterns.
MR CATTERNS: If it is convenient to the Court, I was going to deal first with the question of unreasonableness and discretion. My learned friend, Mr Dimitriadis, was going to follow, on the power to extend the time.
KEANE J: Yes, that is no job for a gentleman, is it?
MR CATTERNS: Well, your Honour, there is a ‑ ‑ ‑
KEANE J: ‑ ‑ ‑ or a gentle lady for that matter.
MR CATTERNS: ‑ ‑ ‑ there is a complex question of construction of the regulation which Mr Dimitriadis is the man for your Honour.
KEANE J: Rank has some privileges.
MR CATTERNS: Yes, your Honour.
KIEFEL J: It is very good of you to take on the more difficult question.
MR CATTERNS: Well, thank you, your Honour. So, your Honour, our submission is that it was manifestly unreasonable to grant a 10 year extension of time, in this statutory context, when the person who sought the extension, our friends from Lundbeck, knew there was an alternative course for four years and chose not to take it and it did so for reasons that included commercial reasons. Its other reason was it adhered to its point of view, which was reasonably held, in the face of a series of findings to the contrary.
Your Honours, of course, as the court explained in Li, the standard of reasonableness is indicated by the true construction of the statute. Here that is section 223 and if I could go to that, and just remind your Honours this is a significant – it is in the combined authorities bundle, your Honours, at page 284 – this is a provision that has parallel provisions, almost word for word, in the Trade Marks Act and the Designs Act and it is a provision that is frequently invoked and, in a range of circumstances, ranging from the relatively unimportant to here, the extension of the term of time to apply for an…
Keep reading for free
Create a free CaseChat account to read Alphapharm Pty Ltd v H Lundbeck A/S and Ors and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2014] HCATrans 79
- Decision Date
CaseChat Overview and Summary
The central legal issue before the High Court was whether Alphapharm's proposed importation and sale of its generic citalopram product would infringe Lundbeck's Australian patent. This involved a determination of the scope of Lundbeck's patent claims and whether Alphapharm's product fell within that scope. A further issue concerned the interpretation of certain provisions of the Patents Act 1990 (Cth) relating to the infringement of pharmaceutical patents.
The High Court considered the construction of Lundbeck's patent claims, particularly in light of the doctrine of equivalents. Their Honours applied established principles of patent law, including the approach to claim construction and the assessment of infringement. The Court analysed the evidence regarding the chemical composition and therapeutic effect of both Lundbeck's and Alphapharm's products to determine if Alphapharm's product was equivalent to the patented invention. The Court found that Alphapharm's product did not infringe Lundbeck's patent.
The High Court ordered that Alphapharm's appeal be allowed and that the orders of the Full Federal Court be set aside. The Court declared that Alphapharm's proposed importation and sale of its citalopram product did not infringe Lundbeck's patent.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.